Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by MetzGERon Mar 11, 2020 12:02pm
48 Views
Post# 30793562

RE:RE:RE:WHERE DO WE GO FROM HERE

RE:RE:RE:WHERE DO WE GO FROM HERE@Inv3strr please stay ans constructive as you have been always. You have to understand the behavior of lv_416. If you bought shares at maybe 2$ you would also be very disappointed.

i have to agree with lv_416 opinion about trial results. They are not good as I hoped too. If you look at the before and after picture of the injected area where do you can see an improvement?! Everybody here want nice RCH-01 results and when you are reading on shiseidos hompeage „such as cure for hair baldness“ then the results ar indeed very disappointing.

nevertheless the reaction of SHISEIDO and Replicel is promising but I really have difficulties to see their plan with that.
i hope they have a plan to make a MUCH better product for commercialization
Bullboard Posts